Quotient Ltd represents a set of core values and corporate philosophy that guide its operations. The company emphasizes innovation, aiming to develop and deliver novel solutions in the diagnostics field. With a strong focus on precision medicine, Quotient Ltd also prioritizes accuracy and reliability in its products and services. The company values collaboration and partnerships, continually seeking to forge relationships that drive advancements in healthcare. Furthermore, Quotient Ltd is committed to high ethical standards, ensuring transparency and integrity in its conduct. By embodying these values and corporate philosophy, Quotient Ltd strives to make a positive impact in the healthcare industry.

Quotient Ltd is primarily present in various countries and regions across the globe. The company has a global presence, with significant operations in the United States, Europe, and Asia-Pacific. Quotient Ltd has established a strong foothold in these key markets, allowing it to effectively serve its customers and expand its reach. With a wide presence in multiple countries and regions, Quotient Ltd continues to strengthen its position as a prominent player in the stock market industry.

Quotient Ltd, a leading diagnostics company, has achieved several significant milestones. The company introduced MosaiQ, its game-changing platform which revolutionizes transfusion diagnostics. Quotient Ltd successfully launched the MosaiQ Early Warnings Score, a novel risk stratification tool for assessing disease severity in critically ill patients. The company also achieved CE Marking for the MosaiQ™ Zika and Calibrator Panel, reinforcing its commitment to advancing diagnostics for infectious diseases. Quotient Ltd's collaborations with renowned institutions have further contributed to its success, including partnerships with Ortho Clinical Diagnostics and the Red Cross. These milestones showcase Quotient Ltd's dedication to innovation and its impact on improving patient outcomes in the field of diagnostics.

Quotient Ltd is a renowned company with a rich history and background. It was founded in 2007 and is headquartered in Eysins, Switzerland. Originally known as Inverness Medical Innovations, the company rebranded as Alere Inc. in 2011 before becoming Quotient Limited in 2017. Quotient is a commercial-stage diagnostics company that focuses on transforming transfusion diagnostics, delivering innovative products to optimize patient care. With its cutting-edge technology and expertise, Quotient aims to address unmet needs in blood typing and screening, helping to improve the safety and efficiency of transfusion medicine. Quotient Ltd continues to make significant contributions in the field of diagnostics and healthcare.

Some of the main competitors of Quotient Ltd in the market include companies like Hologic Inc., Immucor Inc., and Grifols S.A. These companies also operate in the field of diagnostics and blood testing solutions, potentially competing with Quotient Ltd in terms of product offerings and market share. However, Quotient Ltd has built a strong reputation and market presence with its innovative technologies and services.

Quotient Ltd is primarily active in the field of diagnostics and healthcare. As a global leader, Quotient specializes in developing innovative products and technologies for blood grouping and infectious disease testing. The company provides customized solutions to the blood transfusion and transplantation markets, ensuring the safety and accuracy of patient testing. With a focus on enhancing efficiency and reducing costs, Quotient offers a comprehensive range of products that cater to the needs of healthcare providers worldwide. Through their cutting-edge solutions, Quotient Ltd plays a crucial role in improving public health outcomes and supporting healthcare professionals in diagnosing and treating patients effectively.

The business model of Quotient Ltd focuses on the development and commercialization of innovative transfusion diagnostics solutions. Quotient's MosaiQ™ technology platform enables the provision of a wide range of serological tests on a single system. This advanced platform merges automated microarray technology with proprietary chemistry and software, allowing for high-throughput testing and efficient resource allocation. With its unique offering, Quotient Ltd aims to enhance patient outcomes and optimize laboratory efficiency in the field of blood transfusion diagnostics.

Quotient KGV ir -0,00.

Quotient KUV ir 0,00.

AlleAktien kvalitātes vērtējums Quotient ir 7/10.

gaidāmā Quotient apgrozījums ir 72,75 milj. USD.

gaidāmā Quotient peļņa ir -93,76 milj. USD.

Quotient Ltd is a global company that offers innovative technologies and services for the pharmaceutical and biotech industry. The company employs over a thousand employees and is headquartered in Eysins, Switzerland. Its business model includes various divisions, with a focus on science, research, and the development of drugs and biotech products. The main areas of business are drug development services, manufacturing sciences & services, diagnostic solutions, immunoassays & bioassays, and digital health and AI. Quotient Ltd has developed a wide range of products for use in various fields, including assay ready cells, transfection reagents and electrodes, particle cleaning and analysis devices, and various assays and tests for genetic variations and drug determination. The company aims to push the boundaries of science and research and improve the effectiveness of drugs and biotech products. Through continuous investments in research and development, innovative technologies and services, and a focus on customer needs, Quotient Ltd has successfully positioned itself as a leading provider in the biotech industry. The company's $100 million in revenue and collaborations with global players such as GSK, Merck, and Sanofi attest to its economic success.

Quotient izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Quotient vai uzņēmums nedod dividendes.

Quotient ISIN ir JE00BLG2ZQ72.

Quotient WKN ir A11598.

Quotient simbols ir QTNT.

Pēdējo 12 mēnešu laikā Quotient maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Quotient plāno maksāt dividendes 0 USD apmērā.

Quotient pašreizējā dividendu rentabilitāte ir .

Quotient maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Quotient pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Quotient tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Quotient apmērā 0 USD, kas tika izmaksāta 5.10.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 5.10.2024..

Pēdējās dividendes izmaksa notika 5.10.2024..

Gadā 2023, Quotient izmaksāja 0 USD dividendes.

Quotient dividendes tiek izmaksātas USD.